改良PAGE-B评分可预测接受抗病毒治疗的亚洲慢性乙型肝炎患者肝细胞癌风险
该研究纳入2007至2017年接受恩替卡韦或替诺福韦治疗的3001例亚洲慢性乙型肝炎患者,验证PAGE-B评分与多伦多HCC风险指数(THRI),并基于年龄、性别、血小板计数和血清白蛋白水平开发改良PAGE-B评分(mPAGE-B)。mPAGE-B的5年AUROC为0.82,显著高于其他五种模型。
要点
- mPAGE-B评分基于年龄、性别、基线血小板计数和治疗开始时血清白蛋白水平。
- mPAGE-B评分范围0至21分,低风险≤8分,高风险≥13分,可区分5年HCC风险。
- 在验证集中,mPAGE-B的5年AUROC为0.82,显著高于PAGE-B、THRI、CU-HCC、GAG-HCC和REACH-B。
核心结论
- PAGE-B和THRI适用于接受恩替卡韦或替诺福韦治疗的亚洲慢性乙型肝炎患者,但包含血清白蛋白水平的mPAGE-B评分预测性能优于PAGE-B评分。
研究设计与样本
- 研究纳入2007至2017年接受恩替卡韦或替诺福韦治疗的3001例亚洲慢性乙型肝炎患者,其中推导集2001例,验证集1000例。
- 基于多变量Cox模型开发mPAGE-B评分,并进行内部验证(Bootstrap法)和外部验证。
主要发现
- 推导集和验证集的5年累积HCC发生率分别为6.6%和7.2%。
- 在推导集中,年龄、性别、血清白蛋白水平和血小板计数与HCC独立相关。
- 在验证集中,PAGE-B和THRI的5年AUROC分别为0.72和0.73,与CU-HCC(0.70)、GAG-HCC(0.71)和REACH-B(0.61)相似(除REACH-B外,所有p>0.05)。
- mPAGE-B的5年AUROC为0.82,显著高于其他五种模型(所有p<0.01)。
- 长期随访中,接受恩替卡韦或替诺福韦治疗后,所有风险组的HCC发生率均显著降低。
关键数值与推荐
- mPAGE-B评分范围0至21分,低风险≤8分,高风险≥13分,可区分5年HCC风险。
临床怎么用
- mPAGE-B评分仅基于治疗开始时患者的年龄、性别、基线血小板计数和血清白蛋白水平,是预测亚洲慢性乙型肝炎患者抗病毒治疗前5年HCC发生的可靠且易获取的风险评分。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Recently, the PAGE-B score and Toronto HCC risk index (THRI) have been developed to predict the risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB). We aimed to validate PAGE-B scores and THRI in Asian patients with CHB and suggested modified PAGE-B scores to improve the predictive performance. METHODS: From 2007 to 2017, we examined 3,001 Asian patients with CHB receiving entecavir/tenofovir therapy. We assessed the performances of PAGE-B, THRI, CU-HCC, GAG-HCC, and REACH-B for HCC development. A modified PAGE-B score (mPAGE-B) was developed (derivation set, n = 2,001) based on multivariable Cox models. Bootstrap for internal validation and external validation (validation set, n = 1,000) were performed. RESULTS: The five-year cumulative HCC incidence rates were 6.6% and 7.2% in the derivation and validation datasets after entecavir/tenofovir onset. In the derivation dataset, age, gender, serum albumin levels, and platelet counts were independently associated with HCC. The mPAGE-B score was developed based on age, gender, platelet counts, and serum albumin levels (time-dependent area under receiver operating characteristic curves [AUROC] = 0.82). In the validation set, the PAGE-B and THRI showed similar AUROCs to CU-HCC, GAG-HCC, and REACH-B at five years (0.72 and 0.73 vs. 0.70, 0.71, and 0.61 respectively; all p >0.05 except REACH-B), whereas the AUROC of mPAGE-B at five years was 0.82, significantly higher than the five other models (all p <0.01). HCC incidence rates after initiation of entecavir/tenofovir therapy in patients with CHB were significantly decreased in all risk groups in long-term follow-up periods. CONCLUSION: Although PAGE-B and THRI are applicable in Asian patients with CHB receiving entecavir/tenofovir therapy, mPAGE-B scores including additional serum albumin levels showed better predictive performance than the PAGE-B score. LAY SUMMARY: PAGE-B scores and Toronto HCC risk index were developed to predict the risk of hepatocellular carcinoma (HCC) in Caucasian patients with CHB under potent antiviral therapy. This study validated these two scores in Asian patients with CHB and suggested that modified PAGE-B scores could improve the predictive performance. A modified PAGE-B score, which is based only on a patient's age, gender, baseline platelet counts, and serum albumin levels at treatment initiation, represents a reliable and easily available risk score to predict HCC development during the first five years of antiviral treatment in Asian patients with CHB. With a scoring range from 0 to 21 points, a modified PAGE-B score differentiates the HCC risk. A modified PAGE-B score significantly differentiates the five-year HCC risk: low ≤8 points and high ≥13 points.
引用
- Kim JH, Kim YD, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018. PMID: 30075230. doi:10.1016/j.jhep.2018.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。